Finance

Beta
Lists
086450:KOSDAQ
Dongkook Pharmaceutical Co Ltd
â‚©18,430.00
+1.26%
(+230.00) 1D
Jun 11, 2:30:36 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 086450...
Open
â‚©18,030
High
â‚©18,950
Low
â‚©17,740
Mkt. cap
834.05B
Avg. vol.
393.61K
Volume
1.17M
Dividend
1.09%
Quarterly dividend
â‚©50
Ex-dividend date
Dec 29, 2025
P/E ratio
11.10
52-wk high
â‚©31,250
52-wk low
â‚©16,260
EPS
â‚©1,660
Shares outstanding
45.23M
No. of employees
1K
Open
â‚©18,030
High
â‚©18,950
Low
â‚©17,740
Mkt. cap
834.05B
Avg. vol.
393.61K
Volume
1.17M
Dividend
1.09%
Quarterly dividend
â‚©50
Ex-dividend date
Dec 29, 2025
P/E ratio
11.10
52-wk high
â‚©31,250
52-wk low
â‚©16,260
EPS
â‚©1,660
Shares outstanding
45.23M
No. of employees
1K
News stories
From sources across the web
About Dongkook Pharmaceutical Co Ltd
CEOSong Jun-ho
Employees1.31K
FoundedOct 1968
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
233.46B
226.81B
242.88B
251.02B
Cost of goods sold
109.17B
102.50B
110.08B
110.26B
Cost of revenue
109.17B
102.50B
110.08B
110.26B
Research and development expenses
8.01B
8.28B
8.80B
9.46B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
90.36B
88.07B
96.34B
100.54B
Operating expense
102.23B
99.51B
108.50B
113.42B
Total operating expenses
211.40B
202.01B
218.58B
223.68B
Operating income
22.06B
24.80B
24.30B
27.34B
Other non operating income
-8.14B
3.51B
-1.85B
-178.54M
EBT including unusual items
23.28B
28.78B
17.81B
30.18B
EBT excluding unusual items
15.11B
28.79B
21.91B
29.02B
Income tax expense
5.22B
6.46B
2.23B
3.87B
Effective tax rate
22.43%
22.43%
12.50%
12.83%
Other operating expenses
437.80M
450.17M
429.71M
278.11M
Net income
15.77B
19.95B
13.85B
24.95B
Net profit margin
6.75%
8.80%
5.70%
9.94%
Earnings per share
-
-
-
-
Interest and investment income
1.26B
-
1.48B
1.48B
Interest expense
-479.48M
-
-412.07M
-332.99M
Net interest expenses
783.48M
-
1.06B
1.14B
Depreciation and amortization charges
2.00B
1.93B
2.03B
2.01B
EBITDA
29.95B
32.81B
32.62B
35.69B
Gain or loss from assets sale
-5.55B
10.69M
57.84M
16.24M
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more